Open-label placebo is an evidence-based treatment option for many chronic conditions.

Last updated on 07/28/2025
PubMed

Selected Publications

Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them
Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.

330 Brookline Avenue

Boston, MA, 02215